厄贝沙坦联合胺碘酮对阵发性房颤患者转律及窦性心律维持的临床研究

摘要

Objective To discuss the clinical effect of irbesartan combined with amiodarone in rebuilding and maintaining sinus rhythm in patients with paroxysmal atrial ifbrillation.Methods 100 patients with paroxysmal atrial ifbrillation randomly were divided into control group (n=48) and therapeutic group (n=52).Both groups received amiodarone, therapeutic group received irbesartan additionally.All patients were follwed up for 1year. The diameter of left atrium (LAD), left ventricular ejection fraction (LVEF) and the level of hs-CRP were counted, The rate of successful sinus rhythm rebuilding and its maintenance were also observed.Results Compared with the control group, the LAD decreased and LVEF improved in therapeutic group, the rate of successful sinus rhythm and its maintenance were signiifcantly increased. The level of hs-CRP in both groups was lower, especially in the therapeutic group.Conclusion Irbesartan combined with amiodarone can inhibit atrial remodeling obviously, improve heart function, increase the rate of in the rebuilding of sinus rhythm and decrease its recurrence rate signiifcantly, which is more effective than amiodarone alone.%目的：探讨厄贝沙坦联合胺碘酮对阵发性房颤转律及窦性心律维持的临床疗效。方法选择阵发性房颤患者100例，随机分为两组：对照组（48例）和治疗组（52例）。对照组给予胺碘酮治疗，治疗组在应用胺碘酮基础上加服厄贝沙坦治疗。随访1年，观察两组治疗前后左心房内径（LAD）、左室射血分数（LVEF）、血清超敏 C-反应蛋白（hs-CRP）变化、心房颤动转复率及窦性心律维持率。结果治疗组LAD明显缩小、LVEF明显升高，房颤转复率及窦性心律维持率明显优于对照组（P<0.05）；两组治疗后 hs-CRP较治疗前均有下降，但治疗组优于对照组（P<0.05）。结论厄贝沙坦联合胺碘酮可明显抑制心房重构、改善心功能，提高阵发性房颤患者心律转复率，降低复发率，作用优于单独应用胺碘酮，并能有效降低血清 hs-CRP水平。